drugset / Trial / NCT03052842
A Study to Evaluate the Microbiology, Safety and Tolerability of C16G2 Dental Strip Application
Phase 2
Completed
30 enrolled
Armata Pharmaceuticals, Inc.
Agility Clinical, Inc. · collabE Squared Trials and Registries, Inc. · collabVantage Data Designs, Inc. · collab
RandomizedSequentialSingle-blindTreatment
Summary
Single-blind study to evaluate whether C16G2 Strip administered in multiple doses can effectively kill the bacteria in the oral cavity that cause dental caries..
Timeline
- Start
- 2017-02-09
- Primary completion
- 2017-04-05
- Completion
- 2017-04-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | C16G2 | Peptide | 9.2 mg | — |
| Subject | C16G2 | Peptide | 18.4 mg | — |
| Subject | C16G2 | Peptide | 36.8 mg | — |